Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience

Prilozi / Makedonska akademija na naukite i umetnostite, Oddelenie za biološki i medicinski nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences

Volumn 33, Issue 1, 2012, Pages 303-311

  Crvenkova, S ^a   Ivkovski, Lj ^a   Dimovski, A ^a   Kaeva, B ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84984911634     PISSN: 03513254     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)